Peptide Initiative

Peptide profile · Weight Management

Tirzepatide

The dual-action powerhouse that targets both GIP and GLP-1 receptors, delivering the most dramatic weight loss results ever seen in a medication—averaging over 20% body weight reduction while also crushing blood sugar levels in people with diabetes.

Strong human trialsFDA approved for this use
Approximately 5 daysHalf-life (120 hours)
~80%Bioavailability (subcutaneous)
4813.45Molecular weight, g/mol

Molecular formula

C225H348N48O68

CAS number
2023788-19-2
PubChem
168009818
Developed · 2016
Eli Lilly Research Team, Eli Lilly and Company

Amino acid sequence

Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-Ile-Ala-Gln-Lys(C20 fatty diacid-γGlu-2xOEG)-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2

Weight LossProduces 20%+ average body weight loss at the highest dose—the most effective weight loss medication ever approved, approaching surgical results

9.9

Appetite ControlDual GIP/GLP-1 activation creates powerful, sustained appetite suppression that makes portion control feel effortless rather than a constant battle

9.7

Blood Sugar ControlOutperformed semaglutide head-to-head for diabetes management, with HbA1c reductions exceeding 2 percentage points in clinical trials

9.6

Ratings out of 10.

2.5 – 15mg

Every documented dose level

PhaseDoseFrequency
First 4 weeks2.5 mgOnce weekly
Increase by 2.5 mg after at least 4 weeks at each dose5-10 mgOnce weekly
Ongoing maintenance12.5-15 mgOnce weekly
Build my protocolBuild my protocol opens your schedule and dose log to save, share and keep on your phone.

Best for maximum weight loss results & long-term obesity management

Best for

  • People Who Want Maximum Weight Loss Results

    If you're serious about losing significant weight, tirzepatide delivers results that were previously only achievable through bariatric surgery. Clinical trials showed average weight loss exceeding 20% of body weight—that's 50+ pounds for someone starting at 250 pounds. No other medication comes close .

  • Those Who Haven't Succeeded with Semaglutide

    Thanks to its dual GIP/GLP-1 mechanism, tirzepatide often works better for people who had limited results with GLP-1-only drugs like semaglutide. The added GIP activation provides extra metabolic benefits that can break through plateaus and deliver superior weight loss .

  • People with Type 2 Diabetes Needing Aggressive Control

    Head-to-head trials proved tirzepatide beats semaglutide for blood sugar control. The average HbA1c reduction of over 2 percentage points means many people can dramatically reduce or eliminate other diabetes medications. It's a genuine game-changer for metabolic health .

  • Individuals Looking to Transform Their Relationship with Food

    Tirzepatide doesn't just reduce hunger—it fundamentally changes how food appeals to you. Users describe feeling free from constant food thoughts, finding it easy to stop eating when satisfied, and losing interest in formerly irresistible treats. It's not willpower—it's biochemistry working for you .

Consider alternatives if

Weight loss with single-target GLP-1 approachSemaglutide (Wegovy/Ozempic)Liraglutide (Saxenda)Dulaglutide (Trulicity)
Non-injectable weight loss optionsOral semaglutide (Rybelsus)Phentermine-topiramate (Qsymia)Naltrexone-bupropion (Contrave)
Lower cost GLP-1 optionsSemaglutide (may have more coverage options)Liraglutide (Saxenda)Generic liraglutide when available

Do not use if

  • You or a family member has had medullary thyroid carcinoma (MTC)—tirzepatide caused thyroid tumors in animal studies
  • You have Multiple Endocrine Neoplasia syndrome type 2 (MEN2)—elevated thyroid cancer risk
  • You've had a serious allergic reaction to tirzepatide or any GLP-1/GIP medication
  • You currently have or recently recovered from pancreatitis—incretin drugs may increase risk
  • You are pregnant or trying to become pregnant—stop tirzepatide at least 1 month before conception
  • You are breastfeeding—it's unknown if tirzepatide passes into breast milk

Use with caution if

  • You have a history of gallbladder disease or gallstones—rapid weight loss increases gallstone risk significantly
  • You have diabetic retinopathy—rapid blood sugar improvement can temporarily worsen eye problems
  • You take insulin or sulfonylureas—doses will likely need reduction to prevent dangerous low blood sugar
  • You have severe GI disorders like gastroparesis—tirzepatide substantially slows stomach emptying
  • You have a history of depression or suicidal thoughts—monitor mood changes closely
  • You have kidney disease—GI side effects can cause dehydration that worsens kidney function

Not sure?

Compare Tirzepatide with similar peptides to find the best fit for your goals.

Route

Subcutaneous injection (into the fatty tissue just under the skin)—the pen makes it quick and virtually painless, and you can easily do it yourself at home

Best sites

  • Abdomen (stomach area)—at least 2 inches from belly button, most popular choice
  • Front of thighs—middle section of the upper leg
  • Back of upper arm—outer area, may need assistance from someone else

The Tirzepatide injection guide covers reconstitution · step-by-step technique · storage · a sample daily schedule.

4 common side effects · 3 serious

Emergency signs first, then what this page and MedlinePlus say.

Tirzepatide has been extensively studied in the SURPASS (diabetes) and SURMOUNT (obesity) trial programs, involving thousands of participants over multiple years.

The FDA approved it after thorough safety review. While GI side effects are common (especially during dose increases), they're typically mild to moderate and improve over time. Serious adverse events are rare.

The SURPASS-CVOT trial is ongoing to evaluate long-term cardiovascular outcomes.

Safety data comes from multiple Phase 3 trials with follow-up extending beyond 72 weeks. The overall safety profile is similar to GLP-1-only medications like semaglutide, with GI symptoms being the most frequent issues.

The thyroid tumor risk seen in rodents has not been confirmed in humans, but remains a theoretical concern requiring ongoing monitoring.


Common side effects · experienced by some users

Nausea

The most frequently reported side effect, affecting about 25-30% of users. It's usually worst during the first few weeks and when increasing doses, then typically fades as your body adjusts .

Management
Eat smaller, more frequent meals. Avoid greasy, fried, or heavy foods. Stay upright after eating. Ginger tea or ginger candies can help. The slow dose escalation protocol is designed to minimize this—don't rush the titration.

Diarrhea

Affects about 15-20% of users, particularly during dose increases. Your digestive system is adjusting to significantly slower stomach emptying and changed gut signaling .

Management
Stay well hydrated with water and electrolytes. Avoid caffeine and alcohol which can worsen symptoms. Consider a probiotic. Over-the-counter anti-diarrheals can help if needed. Usually improves within a few weeks.

Decreased Appetite

This is actually how tirzepatide works—it's the intended effect, not a side effect. You'll genuinely feel less hungry and more satisfied with smaller amounts of food .

Management
While reduced appetite is the goal, don't skip meals entirely. Focus on nutrient-dense, protein-rich foods at each meal. Aim for at least 60-80g of protein daily to preserve muscle mass. Set reminders to eat if you're forgetting meals.

Vomiting

About 10-15% of users experience vomiting, especially during the titration phase. Like nausea, it's typically temporary and improves as your body acclimates .

Management
If vomiting is persistent, contact your healthcare provider—they may recommend staying at your current dose longer before increasing. Ensure adequate hydration. Anti-nausea medications may be prescribed if needed.

Serious side effects

Pancreatitis

Rare but serious inflammation of the pancreas. Risk is approximately 0.2-0.5% based on trial data. Symptoms include severe abdominal pain that radiates to the back, often with nausea and vomiting .

Management
STOP tirzepatide immediately and seek emergency medical care if you experience severe, persistent abdominal pain. Do not restart tirzepatide if you've had pancreatitis. People with a history of pancreatitis should not use this medication.

Thyroid Tumors (Theoretical Risk)

Tirzepatide and similar drugs caused thyroid C-cell tumors in rodent studies. Whether this occurs in humans is unknown. After years of clinical use, no clear increase in human thyroid cancer has been detected.

Management
Do not use if you or a family member has had medullary thyroid carcinoma (MTC) or MEN2 syndrome. Report any neck lump, persistent hoarseness, trouble swallowing, or shortness of breath to your doctor immediately.

Less commonGallbladder ProblemsHair Thinning (Telogen Effluvium)

These typically resolve with continued use or dose adjustment.


Stop and seek help if

  • Severe or persistent GI symptoms that prevent adequate nutrition despite dose adjustments and supportive care
  • Signs of pancreatitis—severe abdominal pain radiating to the back requiring emergency evaluation
  • Allergic reaction—rash, hives, itching, facial swelling, or difficulty breathing
  • Signs of thyroid problems—neck lump, persistent hoarseness, difficulty swallowing
  • Pregnancy or planning to become pregnant (stop at least 1 month before attempting conception)
  • Severe kidney problems or persistent dehydration from GI symptoms
  • Your healthcare provider recommends discontinuation for any reason

Tirzepatide is a prescription medication that should only be started, adjusted, or stopped under medical supervision. This information is for education only and does not replace professional medical advice. While stopping tirzepatide abruptly is generally safe, discuss any changes with your healthcare provider. Weight regain is common after discontinuation.


With other peptides

  • CautionSemaglutide and other GLP-1 agonists — Never combine GLP-1 medications—they work through overlapping mechanisms. Combining would dramatically increase side effects without additional benefit.
  • SafeBPC-157 — No direct interaction data exists. BPC-157 is sometimes used for gut healing which could theoretically help with GI side effects, but this is speculative and unstudied.
  • SafeGrowth Hormone Peptides — Limited interaction data available. Both can affect glucose metabolism, so combining should only be done under close medical supervision.

With medications

  • CautionInsulin — Tirzepatide dramatically enhances insulin's blood sugar-lowering effect. Insulin doses typically need reduction of 20-50% or more when starting tirzepatide to prevent dangerous hypoglycemia. Close monitoring essential.
  • CautionSulfonylureas (glipizide, glyburide, glimepiride) — High hypoglycemia risk when combined. Sulfonylurea doses usually need significant reduction. Monitor blood sugar frequently and watch for symptoms of low blood sugar.
  • SafeOral Contraceptives — Tirzepatide's effect on gastric emptying may alter absorption of oral medications. Consider using alternative or backup contraception, especially during dose changes.
  • SafeWarfarin — May affect warfarin absorption and metabolism. Increased INR monitoring recommended when starting tirzepatide or changing doses.
  • SafeAcetaminophen and other oral medications — Significantly delayed gastric emptying may slow absorption of oral medications. Consider timing and discuss with your pharmacist.

With supplements

  • SafeVitamin B12 — Long-term use of incretin medications may reduce B12 absorption. Consider B12 supplementation, especially if you've been on tirzepatide for over a year.
  • SafeFiber Supplements — Can help manage constipation but start slowly—too much fiber too fast can worsen GI symptoms. Psyllium husk is a gentle option.
  • SafeProtein Supplements — Highly recommended to preserve muscle mass during rapid weight loss. Aim for 1g protein per pound of goal body weight, or at least 60-80g daily.
  • SafeElectrolyte Supplements — Helpful if experiencing diarrhea or vomiting to prevent dehydration and electrolyte imbalances.

Strong human trials · first signs weeks 1-4 (2.5mg dose)

Evidence level

Strong human trials

(Phase 3 or FDA approved)

100/100

Regulatory status

FDA approved for this use

Onset of effects

Moderate

(1-2 weeks)


How it works

Your body has two 'fullness hormones' that tell your brain when you've eaten enough: GLP-1 and GIP.

Regular weight loss drugs only mimic one of these. Tirzepatide is special because it copies both hormones at once—like having two keys to unlock the same door. This dual action sends an extra-strong 'I'm satisfied' signal to your brain, making you naturally want to eat much less.

It also slows down how fast food leaves your stomach, so small meals keep you full for hours. The result? You lose weight because your biology is finally working with you instead of against you, and hunger stops being something you have to constantly fight.

The deeper mechanism

Tirzepatide is a 39-amino acid synthetic peptide that acts as a dual GIP/GLP-1 receptor agonist, with GIP activity being the more potent of the two (approximately 5:1 GIP:GLP-1 affinity ratio).

The molecule incorporates key modifications for extended half-life: an aminoisobutyric acid (Aib) substitution at position 2 for DPP-4 resistance, and a C20 fatty diacid chain attached via a glutamic acid spacer at Lys20 for albumin binding.

This yields a half-life of approximately 5 days, enabling once-weekly dosing. Mechanistically, GLP-1 receptor activation in hypothalamic neurons (particularly POMC/CART and NPY/AgRP pathways) reduces appetite and food reward.

GIP receptor activation appears to enhance these central effects while also improving insulin sensitivity and potentially facilitating adipose tissue metabolism.

In pancreatic beta cells, both pathways potentiate glucose-dependent insulin secretion while suppressing glucagon from alpha cells. The combination produces synergistic effects on weight loss and glycemic control exceeding what either pathway achieves alone.

Gastric emptying is substantially delayed (more so than with GLP-1 agonists alone), contributing to prolonged satiety.


What to expect

  1. Weeks 1-4 (2.5mg dose)

    What you might notice

    • Mild nausea, especially after eating larger meals
    • Possibly feeling slightly fuller than usual
    • Minimal to no weight loss yet—this is normal and expected
    • Some people feel almost nothing at this dose—that's completely fine

    What's normal

    • GI symptoms that come and go throughout the day
    • Still feeling hungry between meals
    • Weight staying about the same or losing just 1-2 pounds
    • Getting comfortable with your weekly injection routine

    What's next

    • After 4 weeks, increase to 5mg
    • Continue eating normally—don't force dietary changes yet
    • Establish your consistent weekly injection day
  2. Weeks 5-16 (5-10mg doses)

    What you might notice

    • Noticeably reduced appetite and less thinking about food
    • Feeling genuinely satisfied with smaller portions
    • Weight loss becoming visible—typically 5-10% of starting weight
    • GI side effects may briefly intensify with each dose increase, then improve

    What's normal

    • Temporary nausea for a few days after each dose increase
    • Smaller meals feeling completely satisfying
    • Significant reduction in food cravings and snacking urges
    • Clothes starting to fit differently

    What's next

    • Continue gradual dose increases every 4 weeks (5mg → 7.5mg → 10mg)
    • Prioritize protein at every meal to preserve muscle
    • Start noticing how your relationship with food is fundamentally changing
  3. Weeks 17-28 (12.5-15mg doses)

    What you might notice

    • Powerful appetite suppression—you may need reminders to eat
    • Steady, significant weight loss of 2+ pounds per week
    • Food cravings dramatically reduced or absent
    • GI symptoms typically stabilizing by now

    What's normal

    • Eating 30-50% less than before starting, without feeling deprived
    • Much less interest in formerly irresistible foods
    • Visible physical transformation—face, waist, body composition
    • Improved energy and mobility as weight comes off

    What's next

    • Reach the 15mg maximum dose or find your optimal maintenance level
    • Focus on building sustainable long-term eating patterns
    • Incorporate regular physical activity as you feel more energetic
  4. Months 7-12 and beyond

    What you might notice

    • Approaching or exceeding 20% weight loss from starting point
    • Dramatic improvements in metabolic health markers
    • New, healthier relationship with food firmly established
    • Side effects minimal or absent at this stage

    What's normal

    • Weight loss rate slowing as you approach a new equilibrium
    • Maintained reduced appetite at your dose
    • Lab improvements in blood sugar, cholesterol, liver enzymes, inflammation
    • Complete wardrobe replacements and comments from everyone you know

    What's next

    • Continue maintenance therapy—weight typically returns if medication stops
    • Work with your healthcare team on your long-term plan
    • Focus on lifestyle habits that support maintaining your incredible progress

Signs it's working

Appetite and Eating Behavior

  • Feeling genuinely full and satisfied with much smaller portions
  • Fewer food cravings, especially for sweets, snacks, and junk food
  • Reduced 'food noise'—that constant mental chatter about what to eat next
  • Naturally gravitating toward healthier food choices
  • Ability to stop eating when satisfied without internal struggle
  • Less emotional or stress eating

Signs it's working

Weight and Body Composition

  • Scale weight consistently trending downward week after week
  • Clothes becoming loose, needing smaller sizes
  • Visible changes in face shape, waistline, and overall silhouette
  • Waist circumference decreasing measurably
  • Before/after photos showing obvious transformation

Signs it's working

Metabolic Health (via lab tests)

  • Blood sugar levels dropping significantly (HbA1c improving)
  • Blood pressure moving toward healthy range
  • Cholesterol panel improving—lower LDL, lower triglycerides
  • Liver enzymes normalizing if previously elevated
  • Inflammatory markers like CRP decreasing

Not seeing results?

Common reasons

  • Not at therapeutic dose yet—most weight loss occurs at 10-15mg; lower starting doses are just for adjustment
  • Not giving it enough time—significant results typically require 3-6 months of consistent use at higher doses
  • Eating through the medication—forcing yourself to eat large portions despite feeling full defeats the purpose
  • Choosing calorie-dense foods—even smaller portions of high-calorie foods can stall progress
  • Underlying conditions interfering—thyroid disorders, PCOS, certain medications, or hormonal imbalances may slow results
  • Dehydration affecting the scale—ensure adequate water intake for accurate weight readings

260 registered studies, 123 still enrolling.

260registered studies
123recruiting now
89phase 3 or 4
53with published results

By phase

Phase 2

61

Phase 3

45

Phase 4

41

Phase 1

29

Phase 1/2

6

Early Phase 1

5

Phase 2/3

3

No phase

70

A trial spanning two phases is counted in both, so these can sum above the total. Observational studies carry no phase.

What kind of research

Gave the drug

229

Records only

31

About 90,221 people took part in the studies that actually administered Tirzepatide. Observational studies analyse the records of people already taking it — nobody was given anything for the study, so they are counted separately and cannot show cause and effect.


Most recent

  • NCT06180616 Phase 2Not Yet Recruiting40 enrolled

    Tirzepatide for the Treatment of Concurrent Type 1 Diabetes and Overweight or Obesity

    Royal North Shore Hospital

  • NCT07468552 Phase 2Not Yet Recruiting100 enrolled

    Trial of Tirzepatide for the Treatment of Cannabis Use Disorder

    National Institute on Drug Abuse (NIDA)

  • NCT07349641 Phase 2Not Yet Recruiting55 enrolled

    A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer

    National Cancer Institute (NCI)

See all 260 trials for Tirzepatide

Sources: ClinicalTrials.gov, the EU Clinical Trials Information System and ISRCTN, deduplicated so a study registered twice is counted once. A study is counted when Tirzepatide is named as an intervention; studies that only mention it in passing are not.

How much weight will I actually lose on tirzepatide?

Clinical trials showed average weight loss of about 20% of body weight at the highest dose over 72 weeks—that's around 50 pounds for someone starting at 250 pounds. Some people lose even more. Results vary based on starting weight, dose achieved, diet, exercise, and individual factors, but tirzepatide produces the highest average weight loss of any medication ever approved .

How is tirzepatide different from semaglutide (Ozempic/Wegovy)?

While semaglutide only activates GLP-1 receptors, tirzepatide activates both GLP-1 and GIP receptors. This dual-action approach appears to produce greater appetite suppression and weight loss. Head-to-head trials showed tirzepatide users lost about 5-6 more pounds than semaglutide users. Tirzepatide also produced better blood sugar control in people with diabetes .

Why do I have to increase the dose so slowly?

The gradual dose escalation (every 4 weeks) is essential for tolerability. Starting at the full 15mg dose would cause severe nausea and vomiting in most people. By slowly ramping up, your GI system adapts, making side effects much more manageable. Patience during this phase leads to better long-term success.

What happens if I stop taking tirzepatide?

Most people regain significant weight after stopping—studies suggest about two-thirds of lost weight returns within a year. This isn't failure; it's biology. The medication is treating the underlying metabolic and neurological drivers of obesity. When the treatment stops, those drivers return. Most people benefit from long-term maintenance therapy.

Will I lose muscle along with fat?

Some muscle loss occurs with any significant weight loss, including with tirzepatide—roughly 25-40% of weight lost may be lean mass. To minimize this, prioritize protein (aim for at least 1g per pound of goal body weight), do resistance training regularly, and don't skip meals even if you're not hungry.

Is tirzepatide safe for long-term use?

Current data from clinical trials extending beyond 72 weeks shows a consistent safety profile. The SURPASS-CVOT trial is studying long-term cardiovascular outcomes. That said, tirzepatide is newer than semaglutide (approved 2022 for diabetes, 2023 for obesity), so long-term monitoring continues. The safety profile is similar to other GLP-1 drugs in the same class.

Why is there a thyroid cancer warning?

In rodent studies, tirzepatide and similar drugs caused thyroid C-cell tumors. Rodents have many more GIP/GLP-1 receptors in their thyroid than humans. After years of clinical use of this drug class, no clear increase in human thyroid cancer has been observed. Still, tirzepatide is contraindicated if you have a personal or family history of medullary thyroid cancer or MEN2 syndrome .

What's the difference between Mounjaro and Zepbound?

They're both tirzepatide, just approved for different conditions. Mounjaro is approved for type 2 diabetes. Zepbound is approved for chronic weight management in people with obesity or overweight with weight-related conditions. The dosing and medication are identical—only the indication and branding differ.

Ready for the protocol?

Every dosing tier, administration route, timing note, and dose-adjustment rule for Tirzepatide, on one page.

Tirzepatide dosing protocol

Medical disclaimer

Tirzepatide is FDA approved for the use described here. It is a prescription medication that should only be started, adjusted, or stopped under the supervision of a qualified healthcare provider. This information is for educational purposes only and should not be construed as medical advice. Always consult with a qualified healthcare provider before starting any new supplement or treatment protocol.

Last updated: Oct 12, 2026

2.5 – 15 mg Once weekly · onset 1-2 weeks
Open the Tirzepatide calculatorTirzepatide calculator